Moderna (MRNA) shares were down almost 5% in recent trading on Friday after management provided an update on the company's immunotherapy pipeline and presented trial data evaluating its mRNA-4359 cancer vaccine together with pembrolizumab, according to a FactSet transcript of Moderna's oncology investor event.

The company said Monday that mRNA-4359 in combination with pembrolizumab showed "promising" results in its phase 1/2 trial in certain melanoma patients and that it continues to study mRNA-4359 in the phase 2 portion of the ongoing phase 1/2 trial, both as a standalone therapy and in combination with pembrolizumab in patients with advanced melanoma and non-small cell lung cancer.

Moderna expects five-year follow up data to "mature later this year," with data from the phase 2 study expected to be shared "at the end of the year or early in 2026," according to Friday's transcript.

The company is also expanding the study into additional cohorts and combination arms, the transcript said.

Price: 25.81, Change: -1.33, Percent Change: -4.90